The fourth meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses, London, 9-10 November 2009
Presentations
WHO disclaimer:
The designations employed and the presentation of the material on the web only represents the views of the authors and do not imply the expression of any opinion whatsoever on the part of the World Health organization concerning the legal status of any country, territory, city or area or of its authorities.
The World Health organization does not warrant that the information contained in this material is complete and correct and shall not be liable for any damages incurred as a result of its use.
9 November 2009
-
Update on development of H1N1 pandemic vaccines - M-P. Kieny
pdf, 886kb -
Changing antigenicity of HA and NA: opportunities for improved vaccines - D. Smith
pdf, 11.53Mb -
Role of adjuvants in induction of cross-reactive and long-lasting immune responses - M. Friede
pdf, 856kb -
Conserved and alternative vaccine targets - R. Bright
pdf, 1.49Mb -
Immunological correlates of protection - G. Rimmelzwaan
pdf, 1.83Mb -
Role of CMI in protection against influenza in humans - J. McElhaney
pdf, 243kb -
T cell responses in human influenza virus infection - A. McMichael
pdf, 325kb -
Correlates of efficacy of LAIV - K. Subbarao
pdf, 557kb -
M2 cytoplasmic tail mutants as pandemic vaccine candidates - P. Bilsel
pdf, 6.51Mb -
Influenza B NS-1 truncated mutants as candidate vaccines - J. Romanova
pdf, 700kb -
Protease activation mutants of influenza A and B viruses as candidates for attenuated live vaccines against pandemic and seasonal influenza - J. Stech
pdf, 2.24Mb -
Direct and indirect protection against new variants of influenza A and B with the live attenuated influenza vaccine, 2007-2008 - W.-P. Glezen
pdf, 286kb -
Protection against circulating and drifted variants of influenza virus with the LAIV - I. Kiseleva
pdf, 1.08Mb -
AS03-adjuvanted seasonal vaccines in the elderly - D. Poelaert
pdf, 1.20Mb
10 November 2009
-
Enhancing the breadth of immunity to influenza VLPs - D. Compans
pdf, 66kb -
Continuous production and purification of a Virus-Like Particle Influenza vaccine from mammalian cell culture - B. Dropulic
pdf, 7.54Mb -
VLPs made in insect cells and presentation of new clinical data - K. Bryett
pdf, 4.44Mb -
Insect cell-produced influenza-pseudotyped virus like particles: Evidence for enhanced immunity and breadth of protection - J. Haynes
pdf, 2.81Mb -
Overview on safety of live-vectored vaccines - R. Le Blanc
pdf, 474kb -
Live-vector approaches including their MVA vector studies - L. Perera
pdf, 921kb -
MVA vector studies in monkeys - A. Osterhaus
pdf, 5.67Mb -
Rationale and Design of a Phase 1 Clinical Trial of PaxVax Live, Oral Ad4-Vectored H5N1 Vaccine - K. Kelley
pdf, 720kb -
Non-replicating adenovirus vector as a carrier for the development of rapid-response influenza vaccines - D. Tang
pdf, 659kb -
VLP production in plants - L. Vezina
pdf, 4.59Mb -
Vaccines derived from transient gene expression in tobacco plants - V. Yusibov
pdf, 231kb -
A fungal platform for vaccine production - D. Higgins
pdf, 2.19Mb -
A novel universal influenza vaccine containing M2e and NP with a TLR9 agonist - T. Martin
pdf, 214kb -
Flagellin fused M2e vaccines - A. Shaw
pdf, 1.12Mb -
Combined vaccination with split vaccine plus M2e protein - F. Wu
pdf, 485kb -
DNA Vaccines: setback, advances and next steps - J. Beadle
pdf, 3.35Mb -
Improvement of flu vaccine with adjuvants and patch delivery - A. von Gabain
pdf, 1.41Mb -
Nanoemulsion adjuvanted nasal vaccine, a novel means to enhance immunogenicity and broaden cross-protection against influenza - T. Hamouda
pdf, 1.24Mb